MA31470B1 - Dérivés de pipéridine utiles comme antagonistes vis-à-vis des récepteurs de l'orexine - Google Patents

Dérivés de pipéridine utiles comme antagonistes vis-à-vis des récepteurs de l'orexine

Info

Publication number
MA31470B1
MA31470B1 MA32459A MA32459A MA31470B1 MA 31470 B1 MA31470 B1 MA 31470B1 MA 32459 A MA32459 A MA 32459A MA 32459 A MA32459 A MA 32459A MA 31470 B1 MA31470 B1 MA 31470B1
Authority
MA
Morocco
Prior art keywords
antioxidants
useful
orexin receptors
oxidative derivatives
derivatives
Prior art date
Application number
MA32459A
Other languages
Arabic (ar)
English (en)
Inventor
Giuseppe Alvaro
David Amantini
Sandro Belvedere
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0712887A external-priority patent/GB0712887D0/en
Priority claimed from GB0804317A external-priority patent/GB0804317D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31470B1 publication Critical patent/MA31470B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne des dérivés de pipéridines substituées imidazo[1,2-alpha]pyridin-2-ylméthyle et leur utilisation comme produits pharmaceutiques, pour le traitement de l'obésité et du diabète.
MA32459A 2007-07-03 2009-12-30 Dérivés de pipéridine utiles comme antagonistes vis-à-vis des récepteurs de l'orexine MA31470B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0712887A GB0712887D0 (en) 2007-07-03 2007-07-03 Novel compounds
GB0804317A GB0804317D0 (en) 2008-03-07 2008-03-07 Novel compounds
PCT/EP2008/058423 WO2009003993A1 (fr) 2007-07-03 2008-07-01 Dérivés de pipéridine utiles comme antagonistes vis-àvis des récepteurs de l'orexine

Publications (1)

Publication Number Publication Date
MA31470B1 true MA31470B1 (fr) 2010-06-01

Family

ID=39789338

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32459A MA31470B1 (fr) 2007-07-03 2009-12-30 Dérivés de pipéridine utiles comme antagonistes vis-à-vis des récepteurs de l'orexine

Country Status (18)

Country Link
US (2) US20090022670A1 (fr)
EP (1) EP2176258A1 (fr)
JP (1) JP2010531848A (fr)
KR (1) KR20100030635A (fr)
CN (1) CN101796053A (fr)
AR (1) AR067396A1 (fr)
AU (1) AU2008270294A1 (fr)
BR (1) BRPI0812981A2 (fr)
CA (1) CA2691638A1 (fr)
CL (1) CL2008001951A1 (fr)
CO (1) CO6270320A2 (fr)
DO (1) DOP2009000293A (fr)
EA (1) EA201070091A1 (fr)
IL (1) IL202665A0 (fr)
MA (1) MA31470B1 (fr)
PE (1) PE20090441A1 (fr)
TW (1) TW200911242A (fr)
WO (1) WO2009003993A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183246A2 (fr) * 2007-07-27 2010-05-12 Actelion Pharmaceuticals Ltd. Dérivés de 2-aza-bicyclo-[3.3.0]-octane
JP2010540429A (ja) * 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
ES2385699T3 (es) * 2008-02-21 2012-07-30 Actelion Pharmaceuticals Ltd. Derivados de 2-aza-biciclo-[2,2,1]heptano
US20110039857A1 (en) * 2008-04-30 2011-02-17 Hamed Aissaoui Piperidine and pyroolidine compounds
US8129384B2 (en) * 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
EP2358713A1 (fr) * 2008-11-26 2011-08-24 Glaxo Group Limited Dérivés de l imidazopyridazine agissant en tant qu antagonistes de l orexine
WO2010060470A1 (fr) * 2008-11-26 2010-06-03 Glaxo Group Limited Dérivés de la pipéridine utiles en tant qu’antagonistes du récepteur de l’orexine
WO2010060471A1 (fr) * 2008-11-26 2010-06-03 Glaxo Group Limited Dérivés de la pipéridine utiles en tant qu’antagonistes du récepteur de l’orexine
AU2009324238A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
EP2421850A1 (fr) 2009-04-24 2012-02-29 Glaxo Group Limited 3 -azabicyclo [4.1.0]heptanes utilisés comme antagonistes de l'orexine
ME03452B (fr) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disubstitué octahy - dropyrrolo [3,4-c] pyrroles en tant que modulateurs du récepteur de l'orexine
WO2011076744A1 (fr) * 2009-12-21 2011-06-30 Novartis Ag Pyridines accolées à di-substitution hétéroaryle
WO2011138266A1 (fr) * 2010-05-03 2011-11-10 Evotec Ag Dérivés d'indolizine et d'imidazopyridine comme antagonistes de récepteurs d'orexine
CA2815179A1 (fr) * 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Derives de lactame utiles en tant qu'antagonistes du recepteur de l'orexine
WO2012089607A1 (fr) 2010-12-28 2012-07-05 Glaxo Group Limited Nouveaux composés dotés d'un cœur 3a-azabicyclo[4.1.0]heptane agissant sur les récepteurs d'orexine
WO2012089606A1 (fr) 2010-12-28 2012-07-05 Glaxo Group Limited Dérivés azabicyclo [4.1.0] hept-4-yle en tant qu'antagonistes du récepteur humain de l'orexine
GB201101678D0 (en) 2011-02-01 2011-03-16 Rolls Royce Plc A cooling arrangement for a magnetic gearbox
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
EA201500399A1 (ru) 2012-10-10 2015-09-30 Актелион Фармасьютиклз Лтд. Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона
CA2902135A1 (fr) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Derives d'amide d'azetidine en tant qu'antagonistes des recepteurs d'orexine
GB201318222D0 (en) * 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
MY179862A (en) 2013-12-03 2020-11-18 Idorsia Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
AU2016360245B2 (en) 2015-11-23 2020-07-09 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof
MD3426251T2 (ro) 2016-03-10 2022-09-30 Janssen Pharmaceutica Nv Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2
WO2017194548A1 (fr) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de maladies inflammatoires auto-immunes
WO2020007964A1 (fr) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 2-(2-azabicyclo [3.1.0] hexan-1-yl)-1h-benzimidazole
WO2020099511A1 (fr) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Dérivés de benzimidazole-2-méthyl-morpholine
AR129309A1 (es) 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20033437A3 (cs) * 2001-06-28 2004-09-15 Smithkline Beecham P.L.C. N-Aroylové cyklické aminové deriváty jako antagonisté orexinového receptoru

Also Published As

Publication number Publication date
EA201070091A1 (ru) 2010-06-30
AR067396A1 (es) 2009-10-07
AU2008270294A1 (en) 2009-01-08
CO6270320A2 (es) 2011-04-20
TW200911242A (en) 2009-03-16
US20120095034A1 (en) 2012-04-19
IL202665A0 (en) 2010-06-30
CL2008001951A1 (es) 2009-01-09
CA2691638A1 (fr) 2009-01-08
KR20100030635A (ko) 2010-03-18
PE20090441A1 (es) 2009-05-08
DOP2009000293A (es) 2010-03-31
WO2009003993A1 (fr) 2009-01-08
BRPI0812981A2 (pt) 2014-12-16
EP2176258A1 (fr) 2010-04-21
US20090022670A1 (en) 2009-01-22
CN101796053A (zh) 2010-08-04
JP2010531848A (ja) 2010-09-30

Similar Documents

Publication Publication Date Title
MA31470B1 (fr) Dérivés de pipéridine utiles comme antagonistes vis-à-vis des récepteurs de l'orexine
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
EP3252057A3 (fr) Composés multicycliques et leurs procédés d'utilisation
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
GEP20125565B (en) Lactam compounds and their pharmaceutical use
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
GB0510141D0 (en) Novel compounds B3
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
WO2010033168A3 (fr) Composés amides, compositions et utilisations des composés et compositions
WO2007076070A3 (fr) Modulateurs de recepteurs muscariniques
MY150518A (en) Substituted gamma lactams as therapeutic agents
MX2009003981A (es) Agentes moduladores del receptor de calcio.
JO2645B1 (en) Vehicles
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
EA201171210A1 (ru) Производные оксадиазола
WO2008021375A3 (fr) Modulateurs de récepteurs muscariniques
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
WO2007100664A3 (fr) Modulateurs des récepteurs muscariniques
WO2006105035A3 (fr) Modulateurs muscariniques
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
TW200621244A (en) Modulators of muscarinic receptors
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
TW200734323A (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2008152094A3 (fr) Acétamides substitués en tant que modulateurs du récepteur ep2